Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Net Income
Bottom-line profit after all expenses, interest, and taxes.
Exagen Inc.NASDAQ: XGN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$3.97M, compared with -$3.75M a year earlier. Trailing-twelve-month net income was -$20.17M.
Context
- Net income amounted to 30.0% of revenue in FY2025, up 2.8 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$15.58M (+21.9%) for the fiscal year ending Dec 2026, a step up from the -32.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.97M+15.1% QoQ
- Last fiscal yearDec 2025
- -$19.95M-32.0% YoY
- LTMMar 2026
- -$20.17M-30.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5.7% | -7.2% | -1.4 pp |
| 1 year | -32.0% | +21.9% | +53.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (19.95M) USD
- Year-over-year change
- -32.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.95M) | -32.0% |
| FY2024 | 2024-12-31 | (15.12M) | +36.2% |
| FY2023 | 2023-12-31 | (23.69M) | +50.0% |
| FY2022 | 2022-12-31 | (47.39M) | -76.5% |
| FY2021 | 2021-12-31 | (26.85M) | — |
Net Income vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 net income of -$20.17M is the 2nd highest of the 11 companies compared; the peer median is -$35.67M.
- Its year-over-year change of -30.0% is the 8th highest of 10, against a peer median of +14.5%.
- Net income amounts to 29.5% of revenue for XGN, versus a peer median of 43.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$17.17M | +26.3% | — | 41.1% | |
| LTM Mar 2026 | -$20.17M | -30.0% | — | 29.5% | |
| LTM Mar 2026 | -$21.68M | +14.5% | — | 69.5% | |
| FY2025 | -$33.52M | +12.0% | — | 31.1% | |
| LTM Mar 2026 | -$33.58M | -193.9% | — | 31.2% | |
| LTM Mar 2026 | -$34.09M | — | — | 25.2% | |
| LTM Mar 2026 | -$37.25M | +24.6% | — | 46.8% | |
| LTM Jun 2026 | -$51.88M | +50.1% | — | 6.8% | |
| LTM Mar 2026 | -$69.66M | +46.5% | — | 832.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M | -26.6% | — | 871.8% |
| LTM Mar 2026 | -$239.55M | -441.4% | — | 110.0% | |
| Peer median (excluding XGN) | -$35.67M | +14.5% | — | 43.9% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.